Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q3 FY26 Earnings Presentation
28 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Jan 16, 2026
Slide 1: Cover letter to National Stock Exchange
January 16, 2026 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company’s presentation on financial results for the quarter ended on
Slide 2: JB Pharma – Q3 FY26 & 9M FY26 Investor Presentation
JB Pharma – Q3 FY26 & 9M FY26 Investor Presentation January 16, 2026 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: JB Pharma – Looking ahead
> Synergistic acquisitions 5.) productivity Domestic outperformer @® g Gl leader A . Strong FCF GOOD PEOPLE 5 Consistency of delivery 9 for C000 HEATH _ Dosage ols op Global regulatory approvals Medicated/Herbal lozenges a p : a Leadership Key therapies Pillar Brands “J B PHARMA ** Dosage forms Stat
Slide 5: JB Pharma at a glance
49 6 40+ Top 5 Brands among top 300 brands Regulated/semi-regulated Global manufacturer of Years of operations with (IQVIA MAT Dec’25 data), markets of presence through medicated/herbal lozenges consistent track record across contributing over 50% of direct operations and representing a substantial
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 27.0% 27.7% 42% 25.0% 24.3% 3,918 21.3% 32% 3,484 18.6% 3,149 29% 27% 15.4% 24% 2,424 22% # 21% 2,043 1,643 1,775 15% 25% 1,413 19% 18% 19% 19% 17% 553 660 449 386 410 13% 139 194 272 1
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 8 25+ 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Infusions Ampules Vials Ointments Cold Rubs Lozenges Sips 6
Slide 8: Q3 FY26 Business Performance
Q3 FY26 Business Performance
Slide 9: CEO's Message
CEO’s Message “ JB Pharma’s domestic formulations business, once again outperformed the Indian pharmaceutical market, driven by broad- based momentum across key chronic therapies and continued strength in our flagship brands. On the international front, while the CDMO business continued its positive
Slide 10: Results Overview: Q3 and 9M FY26
Results Overview: Q3 and 9M FY26 Revenues (INR crores) 9% ◼ JB Pharma registered revenue of INR 1065 crores in Q3 FY26 3,244 2,969 (YoY growth of 11%) and INR 3244 crores in 9M FY26 (YoY growth of 9%) 11% ◼ Domestic formulations business recorded revenue of INR 620 963 1,065 crores vs INR 566 crores
Slide 11: EBITDA Analysis
EBITDA Analysis INR crores Q3 FY26 Q3 FY25 9M FY26 9M FY25 Revenue 1065 963 3244 2969 Reported EBITDA 296 255 906 805 Included in Employee Non-Cash ESOP Charge 9 15 34 41 Benefits expense One off charges on account of the One off charge - - 15 - proposed merger scheme Operating EBITDA* 305 270 955 8
Slide 12: Financial Overview: Q3 and 9M FY26
Financial Overview: Q3 and 9M FY26 Operating EBITDA (INR crores) 29.4% ◼ Operating EBITDA was INR 305 crores in Q3 FY26 (YoY growth of 28.5% 13%) and INR 955 crores in 9M FY26 (YoY growth of 13%) 28.7% 13% 28.1% – Operating EBITDA margin improved to 28.7% for Q3 FY26 846 955 YoY and improved to 29.4
Slide 13: Domestic Business: Q3 and 9M FY26
Domestic Business : Q3 and 9M FY26 Domestic Formulations (INR crores) ◼ Domestic business continued its momentum and registered YoY 11% growth of 10% to INR 620 crores for Q3 FY26 ◼ Domestic business constitutes 60% of overall turnover in 9M FY26 as compared to 59% of revenue in 9M FY25 ◼ JB Pharma
Slide 14: JB continues as one of the fastest growing companies
JB continues as one of the fastest growing companies, maintaining a market beating performance Among top 25, JB is one of the Among the Fastest growing fastest growing pharma Leadership position company as per IQVIA MAT company in the IPM in the covered markets Dec’25 data 12% Vs IPM growth 35% + sh
Slide 15: 6 Brands now rank among the Top 300 in the IPM
6 Brands now rank among the Top 300 in the IPM MAT Dec’22 Value Sales* MAT Dec’25 Value Sales* MAT Dec’22 Rank MAT Dec’25 Rank CILACAR 305 520 #46 #23 RANTAC 333 340 #37 #56 CILACAR-T 129 271 #203 #90 METROGYL 182 235 #119 #121 NICARDIA 131 245 #197 #112 SPORLAC 85 133 #361 #263 14 All data as per I
Slide 16: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 490 crs INR 908 crs INR 395 crs INR 410 crs INR 258 crs INR 327 crs IQVIA MAT Dec’22 IQVIA MAT Dec’25 IQVIA MAT Dec’22 IQVIA MAT Dec’25 IQVIA MAT Dec’22 IQVIA MAT Dec’25 CILACAR T RANTAC DOM METROGYL P CILACAR M RANTAC MPS METROGYL DG CILACAR TC RANTAC RD METRO
Slide 17: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 137 crs INR 252 crs INR 91 crs INR 160 crs INR 66 crs INR 108 crs IQVIA MAT Dec’22 IQVIA MAT Dec’25 IQVIA MAT Dec’22 IQVIA MAT Dec’25 IQVIA MAT Dec’22 IQVIA MAT Dec’25 NICARDIA SPORLAC RAZEL BETA-NICARDIA SPORLAC GG RAZEL -F NICARDIA RETARD SPORLAC ART RAZEL GO
Slide 18: JB Pharma ranks amongst the Top 10 in Cardiac Therapy
JB Pharma ranks amongst the Top 10 in the Cardiac Therapy; 3 brands in top 25 in Cardiology segment #08 MAT Dec’22 MAT Dec’23 MAT Dec’24 MAT Dec’25 #08 4 4 3 3 26 18 14 12 #09 24 17 16 16 #10 #13 3 brands in Top 25 in the Cardiology segment Azmarda is among the top 100 brands in the MAT MAT cardiolo
Slide 19: Good Performance in all Acquired Portfolios
Good Performance in all Acquired Portfolios • Sporlac franchise revenue at INR 160 crores (IQVIA MAT Dec’25) as against INR 88 crores (IQVIA MAT Dec’22), Probiotic growing at CAGR of 22% Portfolio • Lobun growing at 3 years CAGR of 43% (MAT DEC 22- MAT DEC 25) and registered strong YoY growth of 40%
Slide 20: Sporlac franchise nearly doubles in 3 years
Sporlac franchise nearly doubles in 3 years 133 crores Sporlac Franchise 107 crores 100 crores 24% INR 88 crs INR 160 crs 85 crores IQVIA MAT Dec’22 IQVIA MAT Dec’25 18% 7% SPORLAC GG MAT Dec’22 MAT Dec’23 MAT Dec’24 MAT Dec25 SPORLAC PLUS SPORLAC EVA Sporlac brand is now INR 133 crore (IQVIA MAT De
Slide 21: Razel: Another INR 100+ crores growing franchise
Razel: Another INR 100+ crores growing franchise 108 97 77 66 Razel franchise crosses INR 100 crores as per IQVIA MAT Dec’25 data MAT Dec'22 MAT Dec'23 MAT Dec'24 MAT Dec'25 Razel franchise Sales Razel franchise registered YoY growth of 11% as per IQVIA MAT Dec’25 43% 10 crores 8 crores Razel franch
Slide 22: Ophthalmology portfolio from Novartis gaining momentum
Ophthalmology portfolio from Novartis gaining momentum As per IQVIA MAT Dec’25 data, ophthalmology 230 portfolio sales grew 10% to INR 230 crores vs INR 210 crores in MAT Dec’24 Dedicated field force of 100+ personnel 210 deployed to promote the brands MAT DEC 24 MAT DEC 25 As per IQVIA MAT Nov’25 R
Slide 23: International Business: Q3 and 9M FY26
International Business: Q3 and 9M FY26 12% 445 398 20% 306 ◼ International business revenue grew at 12% to INR 445 crores 254 for Q3 FY26 118 117 ◼ International formulations business grew by 20% to INR 306 25 21 crores for Q3 FY26 Total International CDMO API – All the exports businesses viz. South
Slide 24: Q3 and 9M FY26 Financial Performance (Consolidated)
Q3 and 9M FY26 Financial Performance (Consolidated) Particulars Q3 FY26 Q3 FY25 YoY Growth 9M FY26 9M FY25 YoY Growth Revenue from Operations 1065 963 11% 3244 2969 9% Cost of Goods Sold 329 317 4% 1022 995 3% Gross Profit 735 647 14% 2222 1974 13% Gross Profit Margins 69.1% 67.1% 68.5% 66.5% Employ
Slide 25: Dow Jones Sustainability Index (DJSI)
Dow Jones Sustainability Index (DJSI) Recognized as the world’s most respected corporate sustainability benchmark, the ESG(CSA) survey rigorous evaluation covers environmental, social, governance and industry-specific questionnaires, assessing an average of 23 sustainability topics through over 150
Slide 26: JB Pharma's Performance
JB Pharma’s Performance JB Pharma’s S&P Global ESG Score 86 JB Pharma’s ESG score of 86 will rank among the leading pharmaceutical Score Breakdown companies in India and among the leaders in Pharma Globally (Sector: DRG Pharmaceuticals) ESG scores for companies are available at : https://www.spgloba
Slide 27: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Narayan Saraf, Chief Financial Officer segment. Bes
Slide 28: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you CF Xin) www.jbpharma.com
J. B. Chemicals & Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix